Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
Rain Therapeutics’ $125 Million Initial Public Offering
Connect Biopharma’s $219.9 Million Initial Public Offering
Latham & Watkins LLP and Maples and Calder represented Connect Biopharma in the transaction. Global Law Office and Davis Polk advised joint book-running managers. Connect Biopharma...